WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002026262) COMPOSITIONS FOR REDUCING SIDE EFFECTS IN CHEMOTHERAPEUTIC TREATMENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/026262    International Application No.:    PCT/US2001/029754
Publication Date: 04.04.2002 International Filing Date: 24.09.2001
Chapter 2 Demand Filed:    24.04.2002    
IPC:
A61K 47/02 (2006.01)
Applicants: PRO-PHARMACEUTICALS, INC. [US/US]; 189 Wells Avenue, Newton, MA 02459 (US) (For All Designated States Except US).
KLYOSOV, Anatole [US/US]; (US) (For US Only).
PLATT, David [US/US]; (US) (For US Only)
Inventors: KLYOSOV, Anatole; (US).
PLATT, David; (US)
Agent: STRIMPEL, Harriet, M.; Bromberg & Sunstein LLP, 125 Summer Street, Boston, MA 02110-1618 (US)
Priority Data:
60/235,141 25.09.2000 US
Title (EN) COMPOSITIONS FOR REDUCING SIDE EFFECTS IN CHEMOTHERAPEUTIC TREATMENTS
(FR) PROCEDES ET COMPOSITIONS PERMETTANT DE REDUIRE LES EFFETS SECONDAIRES LIES AUX TRAITEMENTS DE CHIMIOTHERAPIE
Abstract: front page image
(EN)A pharmaceutical compound and a process for making the compound is provided where the compound includes a therapeutic agent, a spacer and a galactose, the spacer being covalently linked to the therapeutic agent at a first site on the spacer and covalently linked to the galactose by an ether bond at a second site on the spacer to form a conjugate. The conjugate may be used to treat a subject suffering from a medical condition, so as to reduce the side effects associated with the therapeutic agent by administering an effective dose of the conjugate to the subject so that the side effects in the subject are less then they would have been with the unconjugated therapeutic agent.
(FR)L'invention concerne un composé pharmaceutique et un procédé de fabrication correspondant. Le composé comprend un agent thérapeutique, un espaceur et un galactose. L'espaceur est associé par liaison covalente à l'agent thérapeutique en un premier site, sur l'espaceur, et il est associé de façon covalente au galactose par une liaison éther en un second site, sur l'espaceur, de manière à former un conjugué. On peut utiliser le conjugué pour traiter un sujet malade, afin de réduire les effets secondaires liés à l'agent thérapeutique, par administration d'une dose efficace de conjugué, ce qui donne des effets secondaires moins prononcés qu'avec un agent thérapeutique non conjugué.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)